Saturday, 31 October 2026European Markets

ACTEOS Stock Bullish Momentum With A 10% Jump So Far On Friday

Loading stream...

(vianews) - shares of acteos (cac 40: eos.pa) rose by a staggering 10.25% to €1.56 at 11:39 est on friday, after five consecutive sessions in a row of losses. cac 40 is jumping 0.32% to €7,393.20, after five consecutive sessions in a row of gains. this seems, so far, a somewhat positive trend exchanging session today.

acteos's last close was €1.42, 38.48% below its 52-week high of €2.30.

about acteos

acteos s.a. designs, develops, integrates, and provides software and related services in the field of supply chain management in france, germany, and lebanon. it offers acteos suite, which include forecasting and procurement system for forecast and point of sales/e-business procurement optimization services; transportation management system to organize and manage transport activities; and warehouse management system, a modular solution to manage customers' warehouses. the company also provides mobility, software as a service, hotline, technical project management, and consulting services. acteos s.a. was founded in 1986 and is headquartered in roubaix, france.

earnings per share

as for profitability, acteos has a trailing twelve months eps of €-0.05.

volume

today's last reported volume for acteos is 28017 which is 872.47% above its average volume of 2881.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, acteos's stock is considered to be overbought (>=80).

more news about acteos (eos.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com